FDA Approves PAVBLU — Amgen, Inc

# FDA Approves Amgen's PAVBLU, First Biosimilar Aflibercept for Retinal Disease Treatment Amgen announced FDA approval of PAVBLU (aflibercept-ayyh), the first biosimilar to Regeneron's Eylea, potentially disrupting the lucrative retinal disease market and offering competitive pricing pressure on the anti-VEGF therapy category. The intravitreal injection's entry could reshape treatment economics for conditions like wet age-related macular degeneration and diabetic retinal edema, which generate billions in annual revenue globally